Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-043/02
A01N-025/00
A61K-031/335
A61K-047/00
출원번호
US-0520479
(2006-09-12)
등록번호
US-8853260
(2014-10-07)
발명자
/ 주소
Desai, Neil P.
Soon-Shiong, Patrick
출원인 / 주소
Abraxis BioScience, LLC
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
32인용 특허 :
87
초록▼
In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of susp
In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.
대표청구항▼
1. A pharmaceutical formulation comprising: paclitaxel at a concentration between 5 mg/ml and 15 mg/ml,wherein the pharmaceutical formulation is an aqueous suspension that is stable for at least 3 days under at least one of room temperature or refrigerated conditions, wherein the pharmaceutical form
1. A pharmaceutical formulation comprising: paclitaxel at a concentration between 5 mg/ml and 15 mg/ml,wherein the pharmaceutical formulation is an aqueous suspension that is stable for at least 3 days under at least one of room temperature or refrigerated conditions, wherein the pharmaceutical formulation comprises nanoparticles comprising a solid core of paclitaxel and an albumin coating,and wherein the size of the nanoparticles in the formulation is less than 400 nm. 2. The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation is a stable aqueous suspension reconstituted from a sterile lyophilized powder. 3. The pharmaceutical formulation of claim 2, wherein the pharmaceutical formulation comprises paclitaxel at a concentration of 5 mg/ml. 4. The pharmaceutical formulation of claim 2, wherein the average diameter of the nanoparticles is no greater than 220 nm. 5. The pharmaceutical formulation of claim 2, wherein there is substantially no precipitation of paclitaxel for at least 3 days under at least one of room temperature or refrigerated conditions. 6. The pharmaceutical formulation of claim 1, wherein the average nanoparticle size does not substantially change for at least 3 days under at least one of room temperature or refrigerated conditions. 7. The pharmaceutical formulation of claim 1, wherein the solid core is substantially free of polymeric material. 8. The pharmaceutical formulation of claim 1, wherein the albumin coating has free albumin associated therewith, and wherein a portion of the paclitaxel is contained within the albumin coating and a portion of the paclitaxel is associated with the free albumin. 9. The pharmaceutical formulation of claim 1, wherein at least a portion of the albumin is crosslinked by disulfide bonds. 10. The pharmaceutical formulation of claim 1, wherein the paclitaxel is substantially amorphous. 11. The pharmaceutical formulation of claim 1, wherein the paclitaxel is substantially crystalline. 12. A method of treatment, comprising administering an effective amount of the composition of claim 1 to a patient to treat a tumor. 13. The method of claim 12, wherein the composition is administered parenterally, orally, intravenously, subcutaneously, intraperitoneally, intrathecally, intramuscularly, by inhalation, topically, transdermally, rectally, or vaginally. 14. The method of claim 13, wherein the composition is administered intravenously. 15. The method of claim 14, wherein the pharmaceutical formulation is infused, and the infusion volume is no greater than 200 ml. 16. A method of treatment, comprising administering an effective amount of the composition of claim 1 to a patient to treat breast cancer. 17. The method of claim 16, wherein the composition is administered parenterally, orally, intravenously, subcutaneously, intraperitoneally, intrathecally, intramuscularly, by inhalation, topically, transdermally, rectally, or vaginally. 18. The pharmaceutical formulation of claim 1, wherein the average diameter of the nanoparticles is no greater than about 200 nm. 19. The pharmaceutical formulation of claim 2, wherein the average diameter of the nanoparticles is no greater than about 200 nm. 20. The pharmaceutical formulation of claim 3, wherein the average diameter of the nanoparticles is no greater than about 200 nm. 21. The pharmaceutical formulation of claim 7, wherein the average diameter of the nanoparticles is no greater than about 200 nm. 22. The pharmaceutical formulation of claim 8, wherein the average diameter of the nanoparticles is no greater than about 200 nm. 23. The pharmaceutical formulation of claim 1, wherein the albumin is human albumin. 24. The pharmaceutical formulation of claim 2, wherein the albumin is human albumin. 25. The pharmaceutical formulation of claim 3, wherein the albumin is human albumin. 26. The pharmaceutical formulation of claim 7, wherein the albumin is human albumin. 27. The pharmaceutical formulation of claim 10, wherein the albumin is human albumin.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (87)
Glen John B. (Macclesfield GB2) James Roger (Macclesfield GB2), Anaesthetic compositions containing 2,6-diisopropylphenol.
Kim Sung-Chul,KRX ; Chang Eun-Ok,KRX ; Song In-Suk,KRX ; Pai Chaul-Min,KRX, Biodegradable polymeric micelle-type drug composition and method for the preparation thereof.
Kohn Elise C. (Olney MD) Reed Eddie (Germantown MD) Liotta Lance A. (Potomac MD), Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Composition useful for in vivo delivery of biologics and methods employing same.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Ali Shaukat ; Franklin J. Craig ; Ahmad Imran ; Mayhew Eric ; Bhattacharya Soumendu ; Koehane Gil ; Janoff Andrew S., Hydrolysis-promoting hydrophobic taxane derivatives.
Mayhew Eric (Monmouth Junction NJ) Ali Shaukat (Monmouth Junction NJ) Janoff Andrew S. (Yardley PA), Hydrolysis-promoting hydrophobic taxane derivatives.
Rahman Aquilur (Gaithersburg MD) Rafaeloff Rafael (Tel-Aviv MD ILX) Husain Syed R. (Gaithersburg MD), Liposome encapsulated taxol and a method of using the same.
Rahman Aquilur (Gaithersburg MD) Rafaeloff Rafael (Tel-Aviv ILX) Husain Syed Rafat (Gaithersburg MD), Liposome encapsulated toxol and a method of using the same.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Method for the preparation of fluorocarbon-containing polymeric shells for medical imaging.
Kinsella James L. (Baltimore MD) Sollott Steven J. (Baltimore MD), Method of treating atherosclerosis or restenosis using microtubule stabilizing agent.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champagne IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champagne IL) Desai Neil P. (Los Angeles CA), Methods for in vivo delivery of nutriceuticals and compositions useful therefor.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Soon-Shiong Patrick (Los Angeles CA) Desai Neil P. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of blood substitutes for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champagne IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champagne IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of immunostimulating agents for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of nucleic acids for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of pharmaceutically active agents for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Non-fluorinated polymeric shells for medical imaging.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof.
Desai Neil P. ; Tao Chunlin ; Yang Andrew ; Louie Leslie ; Zheng Tianli ; Yao Zhiwen ; Soon-Shiong Patrick ; Magdassi Shlomo,ILX, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Desai, Neil P.; Tao, Chunlin; Yang, Andrew; Louie, Leslie; Yao, Zhiwen; Soon-Shiong, Patrick; Magdassi, Shlomo, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Bissery Marie-Christine,FRX ; Laborie Michel,FRX ; Vacus Joel,FRX ; Verrecchia Thierry,FRX, Stabilized nanoparticles which may be filtered under sterile conditions.
Kaufman Robert J. (University City MO) Richard Thomas J. (University City MO) Fuhrhop Ralph W. (St. Louis MO), Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GB2 ; Metcalfe James C.,GB2 ; Weissberg Peter L.,GB2 ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Magdassi Shlomo,ILX ; Yang Andrew ; Tao Chunlin ; Desai Neil P. ; Yao Zhiwen ; Soon-Shiong Patrick, Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof.
Magdassi, Shlomo; Yang, Andrew; Tao, Chunlin; Desai, Neil P.; Yao, Zhiwen; Soon-Shiong, Patrick, Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; LaBell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C., Bendamustine derivatives and methods of using same.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; LaBell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C., Bendamustine derivatives and methods of using same.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; Labell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C., Bendamustine derivatives and methods of using same.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; Labell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C., Bendamustine derivatives and methods of using same.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; Labell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C.; McIntyre, Bradley, Bendamustine derivatives and methods of using same.
De, Tapas; Desai, Neil P; Yang, Andrew; Yim, Zachary; Soon-Shiong, Patrick, Compositions and methods for preparation of poorly water soluble drugs with increased stability.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.